A nanoparticle platform towards gut hormone stimulation in the treatment of gastrointestinal disorders

One of the greatest challenges in oral drug delivery involves the development of new drug delivery systems that enable the absorption of therapeutic peptides into the systemic circulation at therapeutically relevant concentrations. During the last years, my group has been working on the stimulation of gut hormones secretion via lipid nanocarriers orally administered as a platform to orally deliver peptides. The goal of this strategy is to stimulate the secretion of gut hormones while simultaneously providing with plasmatic levels of the encapsulating peptide towards an oral delivery alternative to the subcutaneous peptide injection. This represents a novel promising strategy for the treatment of metabolic gastrointestinal disorders, like type 2 diabetes diabetes, metabolic-dysfunction steatotic liver disease or inflammatory bowel disease.